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getting a positive final test result (i.e. wrongly continued). The developed software 
(i.e. R-codes) can easily be applied to other cases.
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Negative ReiMbuRseMeNt CoNsequeNCes FRoM tRial DesigN ChoiCes
Jaksa A., Westbrook L., Daniel K., Ho Y.S.
Context Matters, Inc., New York, NY, USA
Objectives: Health Technology Assessments (HTA) use clinical trial data to deter-
mine comparative efficacy and cost-effectiveness; thus study design plays a roll 
in market access. The objective is to determine how often reimbursement deci-
sions cite trial design defects. MethOds: We analyzed 1,702 HTAs from CADTH, 
G-BA, HAS, NICE, PBAC, and SMC. We examined the clinical assessment rationale 
for the decision and the reimbursement decisions. An explicit trial design defect 
was defined as a clinical assessment of “inappropriate comparator” or “inappro-
priate patient population.” Clinical assessments of lower, uncertain, or unknown 
efficacy or a clinical determination of insufficient or lack of evidence were defined 
as potential trial design defects. Results: Reviews that cited trial defects resulted 
in significantly more negative reimbursement decisions (6.6%) than positive reim-
bursement decisions (0.4%; p< .001). This pattern held true for each individual 
agency examined. G-BA was the agency most likely to cite an explicit trial deficit 
(39%), while HAS was the least likely (0.6%). In addition, significantly more reviews 
that cited a potential trial defect resulted in negative reimbursement decisions (44%) 
than positive reimbursement decisions (5.5%; p< .001). This also held true for each 
agency. Again, G-BA was most likely to note a potential trial defect in reviews (46%) 
while SMC was least likely (6.4%). Among disease conditions with more than 10 
reviews, explicitly cited trial defects were mostly frequently seen in Cystic Fibrosis 
and Parkinson’s Disease (15% and 13%, respectively). Potential trial defects were 
most frequently cited in Atrial Fibrillation and Depression reviews (42% and 39% 
respectively). cOnclusiOns: Explicit and potential trial design issues have nega-
tive consequences for reimbursement outcomes. Negative decisions are more likely 
than positive decisions to cite trial design issues. G-BA is more inclined than other 
agencies to cite these trial design issues when issuing their reimbursement deci-
sions. Manufacturers should consider market-access outcomes when designing 
clinical trials.
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eviDeNCe ResultiNg FRoM ChaRt Review MethoDology aPPlieD 
to NaMeD PatieNt PRogRaMMe PaRtiCiPatioN aND CoMPassioNate 
MeDiCatioN use: PeRi-aPPRoval aPPRoxiMatioN oF Post-MaRket 
PRaCtiCe PatteRNs aND Costs
Stein D.1, Jean-Mary J.2, Goldwin A.E.2, Lau M.R.3, Manson S.3
1UBC: An Express Scripts Company, Dorval, QC, Canada, 2United BioSource Corporation, London, 
UK, 3GlaxoSmithKline Oncology, Uxbridge, UK
Objectives: Compassionate use programmes provide peri-approval drug access 
based on unsolicited physician requests for patients with unmet need. Practice 
pattern evaluations in this context, using chart review methodology, permits the 
collection of pre-approval data outside of clinical trial settings that can approxi-
mate real-world post-market use. Data can be used to inform important economic 
evaluations, value dossiers, and drug safety assessments. MethOds: Study design 
and operational considerations related to chart review studies of compassionate 
use populations have been summarized by evaluating three multi-national case 
studies. Results: The source populations of patients were drawn from compas-
sionate use programmes providing oral anti-cancer therapies. These were initi-
ated pre-approval following positive clinical trial findings. Countries included 
Australia, Belgium, Greece, Ireland, Israel, Italy, The Netherlands, New Zealand, 
Spain, Switzerland and the United Kingdom. Data including patient character-
istics, patterns of care and drug dosing, duration of treatment and reasons for 
treatment discontinuation, overall survival, clinical benefit, progression free sur-
vival and adverse and serious adverse events are being collected to inform health 
economic and other burden of illness assessments. Site and patient selection was 
performed using compassionate use enrollment data, facilitating an efficient study 
start-up. Data were cleaned at point of data entry and via an electronic query pro-
cess in real-time resulting in tailored international datasets. Patients provided con-
sent for their medical data to be used prior to initiating compassionate use therapy, 
and additional ethical approval for the chart review was sought on a local and/
or national level. Chart review study design requires a balance between scientific 
and operational rigor and practicality and feasibility. cOnclusiOns: Peri-approval 
chart review studies of patients in compassionate use programmes offer an impor-
tant opportunity to characterize patterns of use and associated treatment costs as 
well as the clinical impact of investigational medications in non-trial settings to 
inform clinical, health economic and market access decisions.
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Objectives: Scientific research suggests that randomized controlled trials ter-
minated early for benefit considerations systematically overestimate treatment 
effects of the primary outcome. This study assessed whether Health Technology 
Assessment (HTA) agencies accept the increased uncertainty around overall survival 
(OS) estimates in oncology trials arising from early termination. MethOds: Public 
scientific databases were searched to identify scientific articles and pivotal trials 
involving early trial termination. A selection of related HTA appraisals, published 
between January 2011 and February 2014, were analysed. Current scientific evidence 
on the impact of early stopping on outcome estimates was compared to the conclu-
sions made by 11 HTA agencies. Results: Twelve scientific articles, 12 pivotal trials, 
and 31 related HTA appraisals were selected for in-depth analysis. The scientific 
literature suggests that more stringent significance levels in the repeated interim 
the algorithms’ PPV. cOnclusiOns: We have demonstrated that MC/PV algorithms 
can be used to identify PsO patients with a high degree of accuracy, while PsO-AC 
accuracy requires further investigation. Such methods allow researchers to conduct 
retrospective studies in databases where diagnosis codes are absent.
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assessiNg the eFFeCtiveNess oF CouNteR MatChiNg FoR iMPRoviNg 
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Objectives: The nested case-control (NCC) design offers a simple method for 
avoiding unreasonable assumptions in the evaluation of time-dependent treat-
ment effect. Its results are easy to interpret. Its strength rests largely on the appro-
priateness of the controls which are matched to the cases- suggesting a matching 
strategy that ensures maximum number of discordant case-control pairs may be 
more efficient since effect estimation is based entirely on the off-diagonal data of 
the resulting 2x2 tables in the conditional logistic regression. In theory, the more 
off-diagonal pairs that are generated by the random sampling scheme, the more 
improvement we can expect on efficiency. The objective of this study is to assess the 
efficiency of counter-matching on treatment compared with the classical matching 
approach in the NCC design based on results from the cohort design using simulated 
data. MethOds: In each simulation of 1000 patients at 100 replications per run, we 
assumed an underlying event hazard of Weibull distribution using inputted values 
for the scale and shape parameters, treatment, age and sex as the factors. Each 
run involved distinct treatment prevalence of between 10%-50% with event rate 
varying from common to very rare. We compared the proportion of matched pairs 
(at 1 control per case) used in the analyses of the resulting data between the classi-
cal and counter matching strategies. Results: The counter-matched strategy was 
more efficient than the classical approach. The proportion of matched pairs used 
was on average over ten times more and it also gave mean effect estimates which 
were more consistent with the full cohort values, particularly for low treatment 
exposure and rare events. cOnclusiOns: Our results suggest counter matching is 
more efficient and more accurate estimates than classical matching in nested case-
control design. These benefits may be particularly important for studies involving 
rare events or low treatment exposure.
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Objectives: To assess the methodological quality of randomized controlled trials 
(RCTs) published in “Russian Allergology Journal” (RAJ) in 2009-2013. MethOds: 
Retrospective analysis of 96 original publications was carried out. For 8 RCT the 
risks of biases were assessed using the methodology of the Cochrane Collaboration. 
Accuracy of statistical analysis was assessed in accordance with established in 
2009 journal’s requirements, made in accordance with best international prac-
tice. Results: 96 articles were analysed, 8 (8%) of them were identified as RCTs. All 
the RCTs have a high risk of the biases and major mistakes in the statistical analy-
sis. cOnclusiOns: The methodological quality of RCTs is insufficient and needs 
to be improved. We consider that the most important role should play improvement 
of trials’ planning. Collaboration with the experts in clinical trials’ methodology 
is strongly recommended. The analysis empowers researchers to consider exist-
ing experience and to improve methodological quality of RCTs, their relevance to 
international standards.
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siMulatioN oF aN aDDitioNal go/No-go eFFiCaCy iNteRiM aNalysis iN a 
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Objectives: A head-to-head randomized clinical trial (RCT) to evaluate a new 
drug is financially risky, because a positive outcome is uncertain. We simulate 
and evaluate a head-to-head RCT design incorporating an additional go/no-go 
efficacy interim analysis to show the consequences of this additional interim anal-
ysis. MethOds: We simulate the endpoint event-free-survival (EFS) of patients 
in a head-to-head RCT. The decision rule of the additional interim efficacy analy-
sis (i.e. stop or continue) depends on the number of patients (i.e. 300,400 or 500 
patients) and the significance level (i.e. α = 0.05, α = 0.10 or α = 0.20) of the interim 
analysis. The RCT without an interim-analysis has significance level α = 0.05, 
power= 0.86 and sample size 800. Results: Each combination of sample size 
and significance level, which is called a scenario, is investigated by simulating 
2,000 trials of 800 patients. Per simulated scenario we report, among others, the 
“Probability of positive final analysis test result GIVEN negative interim analysis 
test result” (= wrongly stopped) and the “Probability of negative final analysis 
test result GIVEN positive interim analysis test result” (= wrongly continued). 
The results of the first scenario, i.e. an interim analysis at 300 included patients 
and significance level α = 0.05, are as follows. If the actual improvement of the EFS 
hazard rate is 0%, the abovementioned probabilities are 3.65% and 7.85%. An actual 
improvement effect of 5% changes the probability values to 20.25% and 12.80, 
while an actual improvement effect of 10% causes the probability values 28.50% 
and 5.55%. cOnclusiOns: The simulated probabilities were mainly influenced 
by the actual EFS improvement. The smaller the actual outcome improvement, the 
greater the probability of continuing the trial up to 800 included patients without 
